In this retrospective cohort review, we found patients with head and neck cancer who have pre-existing type 2 diabetes requiring insulin at baseline have a high risk of severe diabetes-related complications while receiving CCRT. The gene discussed is INS; the disease is type 2 diabetes mellitus.